Press Releases April 7, 2026 08:00 AM

Enphase Energy Announces Conference Call to Review First Quarter 2026 Financial Results

Enphase Energy schedules Q1 2026 earnings call to discuss financial results and business updates.

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
ENPH

Enphase Energy, a leader in solar microinverter technology and energy management systems, announced it will hold a conference call and webcast on April 28, 2026, to review its first quarter financial results ending March 31, 2026. The company highlighted its global footprint and innovation in solar energy solutions, with over 5.1 million systems deployed worldwide.

Enphase Energy Announces Conference Call to Review First Quarter 2026 Financial Results
ENPH
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Enphase Energy will report its Q1 2026 financial results in a conference call on April 28, 2026.
  • The company is a global leader in microinverter-based solar and battery systems with a strong international presence.
  • Enphase focuses on solar energy, home energy management, EV chargers, and virtual power plant solutions impacting the renewable energy sector.

FREMONT, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company, announced today that it will host a conference call and webcast on Tuesday, April 28, 2026 at 4:30 p.m. Eastern Time to discuss its first quarter 2026 financial results for the period ended March 31, 2026. The live webcast can be accessed on the Enphase Energy Investor Relations website at investor.enphase.com, and a recorded version of the call will also be available there approximately one hour after the call.

What:Enphase Energy’s First Quarter 2026 Financial Results Earnings Conference Call and Webcast  Date: Tuesday, April 28, 2026  Time:4:30 p.m. Eastern Time  Live Call:833.634.5018  International:+1.412.902.4214  Replay:United States/Canada: 855.669.9658
International: +1.412.317.0088
Replay access code: 3923609  

About Enphase Energy, Inc.

Enphase Energy, a global energy technology company based in Fremont, CA, is the world's leading supplier of microinverter-based solar and battery systems, EV chargers, home energy management systems, and virtual power plant (VPP) solutions. Enphase products enable people to harness the sun to make, use, save, and sell their own power, all controlled through the Enphase App. The company revolutionized the solar industry with its microinverter-based technology and has shipped approximately 86.4 million microinverters, with more than 5.1 million Enphase-based systems deployed in over 160 countries. For more information, visit https://enphase.com/.

©2025 Enphase Energy, Inc. All rights reserved. Enphase Energy, Enphase, the “e” logo, IQ, IQ8, and certain other marks listed at https://enphase.com/trademark-usage-guidelines are trademarks or service marks of Enphase Energy, Inc. Other names are for informational purposes and may be trademarks of their respective owners.

Contact:

Zach Freedman
Enphase Energy, Inc.
Investor Relations
[email protected]


Risks

  • Financial results might not meet investor expectations, potentially due to market competition or supply chain issues in the solar industry.
  • Volatility in global markets and changes in energy policies could affect demand for Enphase's products.
  • Technological advancements by competitors could impact Enphase's market share and future growth.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026